Loading
A phase 3 trial of Cetuximab sarotalocan, Pembrolizumab, Carboplatin in head and neck squamous cell carcinoma, run by Rakuten Medical, Inc., now recruiting.
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases is a phase 3 interventional study registered as NCT06699212 by Rakuten Medical, Inc., with 412 participants planned, started 2024-12-24 and due to reach its primary completion in 2028-09. Interventions recorded: ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin, Cisplatin, 5-fluorouracil. Conditions listed: Recurrent Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares Photoimmunotherapy as an in situ vaccine with PD-1 blockade, Recurrent or metastatic head and neck squamous cell carcinoma, Cisplatin, Carboplatin.
Shares Rakuten Medical, Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Docetaxel, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Cisplatin, Carboplatin, Head and neck squamous cell carcinoma.
Shares Docetaxel, Cisplatin, Carboplatin, Pembrolizumab.
Shares Photoimmunotherapy as an in situ vaccine with PD-1 blockade, Cisplatin, Head and neck squamous cell carcinoma, Pembrolizumab.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Rakuten Medical, Head and neck squamous cell carcinoma, Pembrolizumab.